AbbVie

ABBV

市值 US$5044億

AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing.

AbbVie is the exact opposite of a high-yield trap. Its top two drugs together generate more than enough revenue to cover the dividend.

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented NORTH CHICAGO, Ill., Oct. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain.

AbbVie is a resilient Dividend King with a wide moat. It still looks cheap relative to its long-term growth potential.

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

AbbVie's newer drugs are growing fast enough to more than replace Humira revenue. The hardest part of the transition appears to be behind it.

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic health market through its blockbuster obesity treatments.